Advertisement

Clinical investigations of plasma homovanillic acid concentrations

  • M. Davidson
  • R. Kaminsky
  • S. Jaff
  • N. Runyon
  • K. L. Davis

Abstract

Several lines of evidence suggest that abnormalities of central dopaminergic transmission may be involved in the expression of some schizophrenic symptoms. However, elucidation of the role of dopamine (DA) in schizophrenia has eluded investigative efforts. Presently, no accurate and easily repeatable measure of brain DA activity exists. Measurements of CSF homovanillic acid concentrations and determination of growth hormone and prolactin plasma levels, whose secretion is under central dopaminergic control, has major limitations. A more promising technique, positron emission tomography, is not yet available for routine research use.

Keywords

Schizophrenic Patient Cortical Atrophy Homovanillic Acid Schizophrenic Symptom Chronic Schizophrenic Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kendler KS, Heninger GR, Roth RH (1981). Brain contribution to haloperidol-induced increase in plasma homovanillic acid. Eur J Pharmacol, 71, 321–326PubMedCrossRefGoogle Scholar
  2. 2.
    Kendler KS, Heninger GR, Roth RH (1982). Influence of dopamine agonists on plasma and brain levels of homovanillic acid. Life Sci, 30, 2063–2069PubMedCrossRefGoogle Scholar
  3. 3.
    Medina NA, Giachetti A, Shore PA (1969). On the physiological disposition and possible mechanism of the antihypertensive action of debrisoquin. Biochem Pharmac, 18: 891–901CrossRefGoogle Scholar
  4. 4.
    Riddle MA, Leckman JF, Cohen DJ, Anderson M, Ort SI, Caruso KA, Shaywitz BA (1986). Assessment of central dopaminergic function using plasma-free homovanillic acid after debrisoquin administration. J Neural Transm, 67: 31–43PubMedCrossRefGoogle Scholar
  5. 5.
    Maas JW, Contreras SA, Bowden CL, Weintraub JE (1985). Effects of debrisoquin on CSF and plasma HVA concentrations in man. Life Sci, 36: 2163–2170PubMedCrossRefGoogle Scholar
  6. 6.
    Davila R, Zumarrage M, Perea K, Andia I, Friedhoff AJ (1987). Elevation of plasma homovanillic acid level can be detected within four hours after initiation of haloperidol treatment. Arch Gen Pscyh 44: 837–838Google Scholar
  7. 7.
    Friedhoff AJ (1986). A dopamine dependent restitutive system for the maintenance of mental normalcy. Annals of the New York Academy of Sciences, 463: 47–52PubMedCrossRefGoogle Scholar
  8. 8.
    Wolkowitz OM, Breier A, Doran A, Kelose J, Lucas P, Paul SM, Pickar D (1986). Aprazolam Augmentation of Neuroleptic Antipsychotic Effects. Presented at the American College of Neuropsychopharmacology, Washington, DCGoogle Scholar
  9. 9.
    Bannon MJ, Roth RH (1983). Pharmacology of mesocortical dopamine neurons. Pharmacol Rev, 35: 53–68PubMedGoogle Scholar
  10. 10.
    Weinberger DR (1987). Implication for normal brain development for the pathogenesis of schizophrenia. Arch Gen Psych, 44: 660–669Google Scholar
  11. 11.
    Davidson M, Giordani A, Mohs RC, Aryan T and Davis KL (1987b). Control of extraneous factors affecting plasma homovanillic acid concentrations. Psychiatr Res, 20: 307–312CrossRefGoogle Scholar
  12. 12.
    Kendler KS, Mohs RC, Davis KL. The effects of diet and physical activity on plasma homovanillic acid in normal human subjects. Psychiatr Res, 8: 215–223Google Scholar
  13. 13.
    Carlsson A, Lindquist M (1963). Effect of chloropromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol, 20: 140–144CrossRefGoogle Scholar
  14. 14.
    Karoum F, Karson CN, Bigelow LB, Lawson WB, Wyatt RJ (1987). Preliminary evidence of reduced combined output of dopamine and its metabolites in chronic schizophrenia. Arch Gen Psych, 44: 604–607Google Scholar
  15. 15.
    Pickar D, Labarca R, Doran A, Wolkowitz GM, Roy A, Breier A, Linnoila M, Paul SM (1986). Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Arch Gen Psych 43: 669–676Google Scholar
  16. 16.
    Keefe RSE, Mohs RC, Losonczy MF, Davidson M, Silverman JM, Kendler KS, Horvath TB, Nora R, Davis KL (1987). Characteristics of very poor outcome schizophrenia. Am J Psych, 144: 889–895Google Scholar
  17. 17.
    Seeman P, Vepian C, Bergerson C, Rieder P, Jellinger R, Gabriel E, Reynolds GP, Tourtellotte WV (1984). Bimodal distribution of dopamine receptor density in brains of schizophrenics. Sci 225: 728–731CrossRefGoogle Scholar
  18. 18.
    Wong DF, Wagner HN, Tune LE, Dannals RF, Pearlson GD, Links JM, Tamminga CA, Broussolle EP, Ravert HT, Wilson AA, Young TK, Malat J, Williams JA, O’Tauma LA, Snyder SH, Kuhar MJ, Gjedde A (1986). Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Sci, 234: 1558–1563CrossRefGoogle Scholar
  19. 19.
    Pycock CJ, Kerwin RW, Carte CJ (1980). Effect of lesion of cortical dopamine terminals on subcortical dopamine in rats. Nat, 286: 74–77CrossRefGoogle Scholar
  20. 20.
    Bannon MJ, Reinhard JF, Jr., Bunney EF, Roth RH (1982). Unique response to antipsychotic drugs is due to absence of terminal receptors in mesocortical dopamine neurons Nat, 296: 444–446Google Scholar
  21. 21.
    Weinberger DR, Berman KF, Zec RF (1986). Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia: regional cerebral blood flow (rCBF) evidence. Arch Gen Psych, 43: 114–125Google Scholar
  22. 22.
    Berman KF, Zec RF, Weinberger DR (1986). Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. Role of medication, attention and mental effort. Arch Gen Psych, 43: 114–125Google Scholar
  23. 23.
    Volkow ND, Brodie DJ, Wolf AP, Gomez-Mont P, Cancro R, Van Gelder P, Russell JAJ, Overall J (1986). Brain organization in schizophrenia. J Cerebral Blood Flow and Metabolism, 6: 441–446CrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1990

Authors and Affiliations

  • M. Davidson
  • R. Kaminsky
  • S. Jaff
  • N. Runyon
  • K. L. Davis

There are no affiliations available

Personalised recommendations